| Bioactivity | JAK-2-/3-IN-3 (compound ST4j) is a potent JAK2/3 inhibitor with IC50s of 13.00 and 14.86 nM for JAK2 and JAK3, respectively. JAK-2-/3-IN-3 inhibits autophosphorylation of JAK2 and induces apoptosis in a dose- and time-dependent manner. JAK-2-/3-IN-3 can be used in studies of lymph derived diseases and leukemia[1]. |
| Invitro | JAK-2/3-IN-3 (0-100 μM; 72 h) specifically inhibits human erythroleukemia cells with low toxicity to the normal cells[1].JAK-2/3-IN-3 inhibits human erythroleukemia TF1 cell growth via the JAK2/STAT5 signaling pathway[1].JAK-2/3-IN-3 (15.53 μM; 24, 48, 72 h) induces cytotoxicity via apoptosis in a time-dependent manner in TF1 cells[1].JAK-2/3-IN-3 (IC25, IC50, IC75; 24 h) induces cytotoxicity via apoptosis in a dose-dependent manner in TF1 cells[1]. Apoptosis Analysis[1] Cell Line: |
| Name | JAK-2/3-IN-3 |
| Formula | C13H10Cl2N4O2 |
| Molar Mass | 325.15 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |